glp-1 prescriptions growth slowing 2024 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Agonists Market Report 2025-2033,

Wegovy itself is unlikely to cause an immune reaction as it closely resembles a natural human hormone (GLP 1)

By targeting the GLP-1 receptor, they work with your biology instead of against it

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8

Systematic review of the associations between dose regimens and medication compliance